Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Howard I. Scher(Memorial Sloan Kettering Cancer Center), Andrew J. Armstrong(Duke University), Michael A. Carducci(Sidney Kimmel Comprehensive Cancer Center), Dana E. Rathkopf(Memorial Sloan Kettering Cancer Center), Cora N. Sternberg(Cornell University), Kim N.(Asian Institute of Technology), Eric J. Small(CancerCare Manitoba), Karim Fizazi(Université de Lille), Christopher J. Logothetis(The University of Texas MD Anderson Cancer Center), Charles J. Ryan(University of Minnesota), Michael J. Morris(Dana-Farber Cancer Institute), Emmanuel S. Antonarakis(University of Minnesota), David M. Nanus(Cornell University), Glenn Liu(University of Wisconsin Carbone Cancer Center), Susan F. Slovin(Cornell University), Maha Hussain(Northwestern University), Daniel J. George(Duke University), Tomasz M. Beer(Exact Sciences (United States)), Susan Halabi(Duke Medical Center), Philip W. Kantoff(Convergent Science (United States)), Lawrence H. Schwartz(Memorial Sloan Kettering Cancer Center), George Wilding(The University of Texas MD Anderson Cancer Center), Paul G. Corn(Cornell University), Peter S. Nelson(Fred Hutch Cancer Center), Mark N. Stein(Cornell University), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Oliver Sartor(Mayo Clinic), Walter M. Stadler(Project HOPE), Ethan Basch(UNC Lineberger Comprehensive Cancer Center), Robert Dreicer(University of Virginia), Wm. Kevin Kelly(Cornell University), Elisabeth I. Heath(The Barbara Ann Karmanos Cancer Institute), Mary-Ellen Taplin(Dana-Farber Brigham Cancer Center), Celestia S. Higano(University of British Columbia)
Cited by 1,595
Related Papers
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
|New England Journal of Medicine|2010|5.5k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k